ClinicalTrials.gg
Not yet recruitingNCT07939815Updated Nov 16, 2026

A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

A Phase 1/2 interventional study of BMS-986548 and Cetuximab in Advanced Solid Malignancies, sponsored by Bristol-Myers Squibb. Not yet recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
171
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.

Planned enrollment
53rd of 107
171 · median 169
Started
2026
with 8 others
Phase 1/2
19 of 131
5 open now
Primary completion
2029-12
later than 26 of 34 live
Registered
131st of 131
by date

Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 53rd largest by planned enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2026, is one of 19 in phase 1/2, reaches primary completion later than 26 of the 34 other live ones, and was the 131st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, efficacy, and drug levels of BMS-986548 as a monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies.

03

Conditions studied

  • Advanced Solid Malignancies

Keywords

  • Advanced Solid Malignancies
  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a confirmed diagnosis of a locally advanced and unresectable or solid tumor with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).
  • Participants must have an (ECOG) Performance Status of 0 or 1.
  • Participants must have assessed by the investigator using (RECIST) v1.1.
  • Participants should have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed decision) the following Standard of Care (SoC) treatments:.

    i) Part 1A: All appropriate SoC treatments for the disease under study

ii) Part 2A:,

A. Non-Small Cell Lung Cancer (NSCLC): platinum-based doublet chemotherapy and/or PD-(L)1 .

B. Colorectal Cancer (CRC): fluoropyrimidine, oxaliplatin, and/or irinotecan-based chemotherapy, and Vascular Endothelial Growth Factor (VEGF)-targeted antibodies. For participants with dMMR/Microsatellite Instability-High (MSI-H) (or POLE/POLD1 mutation) CRC, a checkpoint inhibitor (PD-[L]1 and/or CTLA-4).

C. Pancreatic Ductal Adenocarcinoma (PDAC): fluoropyrimidine-based chemotherapy with oxaliplatin and irinotecan (may include liposomal formulation) and/or gemcitabine-based chemotherapy with albumin-bound paclitaxel or cisplatin.

iii) Part 1B, Part 2B:,

A. CRC: fluoropyrimidine, oxaliplatin, and/or irinotecan-based chemotherapy, and VEGF-targeted antibodies. For participants with dMMR/MSI-H (or POLE/POLD1 mutation) CRC, a checkpoint inhibitor (PD-[L]1 and/or CTLA-4).

Exclusion criteria

Exclusion Criteria

  • Participants must not have had prior treatment with a (K)RAS directed therapy including approved treatments and agents.
  • Participants must not have untreated central nervous system (CNS) .
  • Participants must not have concurrent (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
  • Participants must not have a history of (non-infectious) Interstitial Lung Disease (ILD)/pneumonitis requiring , current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Participants must not have a history of prior Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
171 participants (estimated)

Study arms

  • Experimental
    Part 1A Monotherapy Dose Escalation: BMS-986548

    Drug: BMS-986548

  • Experimental
    Part 1B Combination Dose Escalation: BMS-986548 + Cetuximab

    Drug: BMS-986548 · Drug: Cetuximab

  • Experimental
    Part 2A Monotherapy Dose Expansion: BMS-986548

    Drug: BMS-986548

  • Experimental
    Part 2B Combination Dose Expansion: BMS-986548 + Cetuximab

    Drug: BMS-986548 · Drug: Cetuximab

Interventions

  • DrugBMS-986548

    Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 30 days after last dose

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 30 days after last dose

  3. Number of participants with AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria

    Time frame: Up to 30 days after last dose

  4. Number of participants with AEs leading to discontinuation

    Time frame: Up to 30 days after last dose

  5. Number of deaths

    Time frame: Up to 30 days after last dose

Secondary outcomes

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  2. Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  3. Maximum observed concentration (Cmax)

    Time frame: Up to 3 years

  4. Time of maximum observed concentration (Tmax)

    Time frame: Up to 3 years

  5. Area under the concentration-time curve within a dosing interval (AUC(TAU))

    Time frame: Up to 3 years

07

Study locations

4 sites
  • Local Institution - 0001
    San Antonio, Texas 78240, United States
    • Site 0001 · Contact
  • Local Institution - 0004
    West Valley City, Utah 84119, United States
    • Site 0004 · Contact
  • Local Institution - 0002
    Vancouver, British Columbia V5Z4E6, Canada
    • Site 0002 · Contact
  • Local Institution - 0003
    Toronto, Ontario M5G2M9, Canada
    • Site 0003 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2029, 36 months later.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 36 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Dec 29, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939815
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 29, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion